PL206379B1 - Ulegająca bioerozji kompozycja do wytwarzania błony do dostarczania leków oftalmicznych i zastosowanie - Google Patents

Ulegająca bioerozji kompozycja do wytwarzania błony do dostarczania leków oftalmicznych i zastosowanie

Info

Publication number
PL206379B1
PL206379B1 PL374764A PL37476403A PL206379B1 PL 206379 B1 PL206379 B1 PL 206379B1 PL 374764 A PL374764 A PL 374764A PL 37476403 A PL37476403 A PL 37476403A PL 206379 B1 PL206379 B1 PL 206379B1
Authority
PL
Poland
Prior art keywords
film
composition
drug
fatty acid
glyceride
Prior art date
Application number
PL374764A
Other languages
English (en)
Polish (pl)
Other versions
PL374764A1 (en
Inventor
Bhagwati P. Kabra
Janet D. Howie
Youqin Tian
David Allen Marsh
Gustav Graff
Original Assignee
Alcon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon filed Critical Alcon
Publication of PL374764A1 publication Critical patent/PL374764A1/xx
Publication of PL206379B1 publication Critical patent/PL206379B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL374764A 2002-07-15 2003-06-30 Ulegająca bioerozji kompozycja do wytwarzania błony do dostarczania leków oftalmicznych i zastosowanie PL206379B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39584002P 2002-07-15 2002-07-15
US43272102P 2002-12-12 2002-12-12

Publications (2)

Publication Number Publication Date
PL374764A1 PL374764A1 (en) 2005-10-31
PL206379B1 true PL206379B1 (pl) 2010-08-31

Family

ID=30118549

Family Applications (1)

Application Number Title Priority Date Filing Date
PL374764A PL206379B1 (pl) 2002-07-15 2003-06-30 Ulegająca bioerozji kompozycja do wytwarzania błony do dostarczania leków oftalmicznych i zastosowanie

Country Status (17)

Country Link
US (1) US8084054B2 (enExample)
EP (1) EP1521572B1 (enExample)
JP (1) JP4454019B2 (enExample)
KR (1) KR101003514B1 (enExample)
CN (1) CN100500221C (enExample)
AT (1) ATE424187T1 (enExample)
AU (1) AU2003247671B2 (enExample)
CA (1) CA2491312C (enExample)
CY (1) CY1109606T1 (enExample)
DE (1) DE60326455D1 (enExample)
DK (1) DK1521572T3 (enExample)
ES (1) ES2321083T3 (enExample)
MX (1) MXPA05000631A (enExample)
PL (1) PL206379B1 (enExample)
PT (1) PT1521572E (enExample)
SI (1) SI1521572T1 (enExample)
WO (1) WO2004006889A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0609432A2 (pt) * 2005-03-21 2010-04-06 Macusight Inc sistemas de distribuição de fármacos para tratamento de doenças ou condições
AU2009246520B2 (en) 2008-05-12 2012-04-19 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
PL2391419T3 (pl) 2009-01-29 2019-12-31 Forsight Vision4, Inc. Dostarczanie leku do tylnego odcinka
MX2013001116A (es) * 2010-07-29 2013-06-05 Santen Pharma Co Ltd Cuerpo para soporte de farmaco, y metodo para producir el mismo.
US9033911B2 (en) 2010-08-05 2015-05-19 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
EP2600812B1 (en) 2010-08-05 2021-09-22 ForSight Vision4, Inc. Apparatus to treat an eye
EP2600876B1 (en) 2010-08-05 2015-04-29 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
JPWO2012153870A1 (ja) * 2011-05-11 2014-07-31 帝人株式会社 緑内障治療材
US20120302954A1 (en) * 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
EP2726016B1 (en) 2011-06-28 2023-07-19 ForSight Vision4, Inc. An apparatus for collecting a sample of fluid from a reservoir chamber of a therapeutic device for the eye
EP2739252A4 (en) 2011-08-05 2015-08-12 Forsight Vision4 Inc SMALL MOLECULE ADMINISTRATION USING AN IMPLANTABLE THERAPEUTIC DEVICE
EP2755600B1 (en) 2011-09-16 2021-03-17 ForSight Vision4, Inc. Fluid exchange apparatus
US10010448B2 (en) 2012-02-03 2018-07-03 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US9822257B2 (en) 2012-07-23 2017-11-21 Crayola Llc Dissolvable films and methods of using the same
US9968603B2 (en) 2013-03-14 2018-05-15 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
JP6385423B2 (ja) 2013-03-28 2018-09-05 フォーサイト・ビジョン フォー・インコーポレーテッド 治療物質送達用の眼移植片
ES2992100T3 (es) 2014-07-15 2024-12-09 Forsight Vision4 Inc Dispositivo de administración de implante ocular
JP2017524034A (ja) 2014-08-08 2017-08-24 フォーサイト・ビジョン フォー・インコーポレーテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ４， Ｉｎｃ． 受容体型チロシンキナーゼ阻害剤の安定で可溶な製剤およびその調製の方法
AU2015346450B2 (en) 2014-11-10 2020-01-30 Forsight Vision4, Inc. Expandable drug delivery devices and method of use
CN113069681B (zh) 2015-11-20 2022-12-23 弗赛特影像4股份有限公司 制造用于缓释药物递送的治疗装置的方法
BR112018070383A2 (pt) 2016-04-05 2019-02-05 Forsight Vision4 Inc dispositivos para aplicação de fármaco oculares implantáveis
WO2019103906A1 (en) 2017-11-21 2019-05-31 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device
AU2023345389A1 (en) * 2022-09-23 2025-04-17 Madd Ophthalmics Ltd. Mucoadhesive drug delivery systems and methods of use

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6042766B2 (ja) 1978-12-09 1985-09-25 日本化薬株式会社 基剤
GB8524421D0 (en) 1985-10-03 1985-11-06 Boots Co Plc Therapeutic agents
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4880636A (en) * 1988-05-13 1989-11-14 Franz Robert M Film coated tablet of ranitidine HCl
US4865846A (en) * 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
US6117425A (en) 1990-11-27 2000-09-12 The American National Red Cross Supplemented and unsupplemented tissue sealants, method of their production and use
SK279279B6 (sk) 1991-05-13 1998-09-09 The Boots Company Plc S(-)-nátrium-2-(4-izobutylfenyl)propionát-dihydrát
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
US5614549A (en) 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
CN1245156C (zh) 1993-02-22 2006-03-15 美国生物科学有限公司 用于体内传送生物制品的方法及用于该方法的组合物
US5665382A (en) 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5362478A (en) 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
US5433951A (en) 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
US5484608A (en) * 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US6063116A (en) 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing
US5783178A (en) 1994-11-18 1998-07-21 Supratek Pharma. Inc. Polymer linked biological agents
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
RU2086218C1 (ru) 1995-07-26 1997-08-10 Санкт-Петербургская медицинская академия последипломного образования Способ лечения глаукомы
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
FR2748209B1 (fr) * 1996-05-06 1998-06-05 Adir Composition pharmaceutique a base de matrices lipophiles stabilisees pour la liberation controlee de principes actifs
ES2248847T3 (es) 1996-05-24 2006-03-16 Angiotech Pharmaceuticals, Inc. Composiciones y metodos para tratar o prevenir enfermedades de las vias de conduccion del cuerpo.
US5888493A (en) * 1996-12-05 1999-03-30 Sawaya; Assad S. Ophthalmic aqueous gel formulation and related methods
DK1023050T3 (da) 1997-06-27 2013-10-14 Abraxis Bioscience Llc Nye formuleringer af farmakologiske midler, fremgangsmåder til fremstillingen deraf og fremgangsmåder til anvendelsen deraf
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US20020164374A1 (en) 1997-10-29 2002-11-07 John Jackson Polymeric systems for drug delivery and uses thereof
US6146659A (en) 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
US6017948A (en) 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
ES2204531T3 (es) * 1999-03-16 2004-05-01 Merck Patent Gmbh Composicion que comprende isoquercetina y acido ascorbico en una forma de liberacion sostenida.
AU777528B2 (en) 1999-04-22 2004-10-21 Abraxis Bioscience, Llc Long term administration of pharmacologically active agents
US6306120B1 (en) 1999-06-07 2001-10-23 Ben Gee Tan Applicator and method for delivery of mitomycin to eye tissues during glaucoma filtering surgery
US6375963B1 (en) * 1999-06-16 2002-04-23 Michael A. Repka Bioadhesive hot-melt extruded film for topical and mucosal adhesion applications and drug delivery and process for preparation thereof
CA2445763A1 (en) * 2001-05-01 2002-11-07 Angiotech Pharmaceuticals Inc. Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions
US20040058313A1 (en) * 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders

Also Published As

Publication number Publication date
SI1521572T1 (sl) 2009-06-30
CA2491312A1 (en) 2004-01-22
MXPA05000631A (es) 2005-03-31
KR101003514B1 (ko) 2010-12-30
CA2491312C (en) 2011-05-31
PT1521572E (pt) 2009-04-21
US8084054B2 (en) 2011-12-27
AU2003247671B2 (en) 2008-02-14
WO2004006889A1 (en) 2004-01-22
CN1668278A (zh) 2005-09-14
JP4454019B2 (ja) 2010-04-21
EP1521572A1 (en) 2005-04-13
EP1521572B1 (en) 2009-03-04
AU2003247671A1 (en) 2004-02-02
KR20050025961A (ko) 2005-03-14
CN100500221C (zh) 2009-06-17
ATE424187T1 (de) 2009-03-15
JP2005533106A (ja) 2005-11-04
ES2321083T3 (es) 2009-06-02
PL374764A1 (en) 2005-10-31
CY1109606T1 (el) 2014-08-13
DE60326455D1 (de) 2009-04-16
US20040126408A1 (en) 2004-07-01
DK1521572T3 (da) 2009-05-04

Similar Documents

Publication Publication Date Title
PL206379B1 (pl) Ulegająca bioerozji kompozycja do wytwarzania błony do dostarczania leków oftalmicznych i zastosowanie
ZA200410095B (en) Bioerodible film for ophthalmic drug delivery
EP2167039B1 (en) Improved depot formulations
US11116776B2 (en) Intravitreal drug delivery systems for the treatment of ocular conditions
US8575092B2 (en) Gelling hydrophobic injectable polymer compositions
JP2007526226A (ja) 生分解性デバイスにおける医薬品の速度制御放出
AU2006341116B2 (en) Gelling hydrophobic injectable polymer compositions
JP2007535367A (ja) エストラジオール誘導体またはエストラトポン誘導体を含有する徐放性眼内インプラント、ならびに関連する製造法
EP2701680A1 (en) Sustained release latanoprost implant
CN1340358A (zh) 长效环孢素眼内释药体系
Pinto et al. An Intraocular Lens-based Biodegradable Drug Delivery System for the Treatment of Post-cataract Inflammation.
US20250222007A1 (en) Preparation of low molecular weight polylactic acid and the use thereof
GR1010308B (el) Φαρμακευτικο σκευασμα που περιλαμβανει τακρολιμους, μεθοδος για την παρασκευη και χρηση αυτου
JP2025525881A (ja) 眼内使用するためのニンテダニブの医薬製剤

Legal Events

Date Code Title Description
RECP Rectifications of patent specification
LAPS Decisions on the lapse of the protection rights

Effective date: 20120630